While in Sydney earlier this month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.
While in Brisbane this week, Anatara Lifesciences CEO Steve Lydeamore (ASX:ANR) sat down with Scott Power, Senior Analyst at Morgans Financial Limited, Australia's largest national full-service retail stockbroking and wealth management network.
Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product
Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.
Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.
Banking & Finance
- YPB Group Ltd (ASX:YPB) Update on YPB Token
- Goldfields Money Ltd (ASX:GMY) Key Operating Metrics - November 2018
- YPB Group Ltd (ASX:YPB) Non-Executive Director Appointment
Oil Gas & Energy
- Deep Yellow Limited (ASX:DYL) Nova JV Annual Budget Approved & Follow-Up Drilling Complete
- EON NRG Ltd (ASX:E2E) Annual Report to shareholders
- EON NRG Ltd (ASX:E2E) Notice of Annual General Meeting/Proxy Form